{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:21:29Z","timestamp":1791476489150,"version":"4.3.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.bcp.2024.116369","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T20:32:25Z","timestamp":1718397145000},"page":"116369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["P2X7 receptor deficiency attenuates cisplatin-induced kidney injury via inhibiting NLRP3 inflammasome activation"],"prefix":"10.1016","volume":"226","author":[{"given":"Yingying","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2024.116369_b0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41581-022-00631-7","article-title":"Cisplatin nephrotoxicity: new insights and therapeutic implications","volume":"19","author":"Tang","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"10.1016\/j.bcp.2024.116369_b0010","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.08070715","article-title":"Long-term renal outcomes after cisplatin treatment","volume":"11","author":"Latcha","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.bcp.2024.116369_b0015","first-page":"CD008944","article-title":"Veening MA: Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer","volume":"3","author":"Kooijmans","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.bcp.2024.116369_b0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1681\/ASN.2021121591","article-title":"Cisplatin-induced kidney injury: Delivering the goods","volume":"33","author":"Curry","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.bcp.2024.116369_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109693","article-title":"Inhibition of CXCL1-CXCR2 axis ameliorates cisplatin-induced acute kidney injury by mediating inflammatory response","volume":"122","author":"Liu","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bcp.2024.116369_b0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.oraloncology.2018.09.015","article-title":"Triggering TLR3 pathway promotes tumor growth and cisplatin resistance in head and neck cancer cells","volume":"86","author":"Chuang","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.bcp.2024.116369_b0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bcp.2017.12.021","article-title":"The P2X7 receptor: A main player in inflammation","volume":"151","author":"Adinolfi","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2024.116369_b0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/ATVBAHA.120.315116","article-title":"P2X7 receptors: An untapped target for the management of cardiovascular disease","volume":"41","author":"Shokoples","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.bcp.2024.116369_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2014.09.016","article-title":"P2X7 receptor blockade protects against cisplatin-induced nephrotoxicity in mice by decreasing the activities of inflammasome components, oxidative stress and caspase-3","volume":"281","author":"Zhang","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.bcp.2024.116369_b0050","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ki.2015.327","article-title":"Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition","volume":"89","author":"Katagiri","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.bcp.2024.116369_b0055","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1038\/s41467-019-10626-x","article-title":"P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis","volume":"10","author":"Martinez-Garcia","year":"2019","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.bcp.2024.116369_b0060","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.bcp.2024.116369_b0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12929-019-0518-9","article-title":"Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity","volume":"26","author":"Volarevic","year":"2019","journal-title":"J Biomed Sci"},{"issue":"1","key":"10.1016\/j.bcp.2024.116369_b0070","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41419-020-03384-y","article-title":"P2X7 receptor signaling promotes inflammation in renal parenchymal cells suffering from ischemia-reperfusion injury","volume":"12","author":"Qian","year":"2021","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.bcp.2024.116369_b0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","article-title":"The P2X7 receptor in infection and inflammation","volume":"47","author":"Di Virgilio","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.bcp.2024.116369_b0080","article-title":"The role of the superior cervical sympathetic ganglion in ischemia reperfusion-induced acute kidney injury in rats","volume":"9","author":"Zhang","year":"2022","journal-title":"Front Med (lausanne)"},{"issue":"2","key":"10.1016\/j.bcp.2024.116369_b0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nri2691","article-title":"The IL-1 family: regulators of immunity","volume":"10","author":"Sims","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.bcp.2024.116369_b0090","doi-asserted-by":"crossref","first-page":"e1000661","DOI":"10.1371\/journal.ppat.1000661","article-title":"IL-1beta processing in host defense: beyond the inflammasomes","volume":"6","author":"Netea","year":"2010","journal-title":"PLoS Pathog"},{"issue":"4 Pt 2","key":"10.1016\/j.bcp.2024.116369_b0095","first-page":"F700","article-title":"Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis","volume":"270","author":"Lieberthal","year":"1996","journal-title":"Am J Physiol"},{"issue":"8","key":"10.1016\/j.bcp.2024.116369_b0100","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bcp.2011.12.008","article-title":"Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells","volume":"62","author":"Lee","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2024.116369_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109101","article-title":"beta-Hydroxybutyrate against Cisplatin-Induced acute kidney injury via inhibiting NLRP3 inflammasome and oxidative stress","volume":"111","author":"Luo","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bcp.2024.116369_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121040","article-title":"Insights into the role of P2X7R\/DUSP6\/ERK1\/2 and SIRT2\/MDM2 signaling in the nephroprotective effect of berberine against cisplatin-induced renal fibrosis in rats","volume":"309","author":"Ahmedy","year":"2022","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.bcp.2024.116369_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2019.07.001","article-title":"NLRP3 inflammasome inhibition attenuates cisplatin-induced renal fibrosis by decreasing oxidative stress and inflammation","volume":"383","author":"Li","year":"2019","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.bcp.2024.116369_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coph.2016.05.001","article-title":"P2 receptors in cancer progression and metastatic spreading","volume":"29","author":"Di Virgilio","year":"2016","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.bcp.2024.116369_b0125","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1158\/0008-5472.CAN-05-3185","article-title":"The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism","volume":"66","author":"Raffaghello","year":"2006","journal-title":"Cancer Res"},{"issue":"41","key":"10.1016\/j.bcp.2024.116369_b0130","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1038\/onc.2014.444","article-title":"The P2X7 receptor is a key modulator of the PI3K\/GSK3beta\/VEGF signaling network: evidence in experimental neuroblastoma","volume":"34","author":"Amoroso","year":"2015","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bcp.2024.116369_b0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3892\/or.2015.3979","article-title":"P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway","volume":"34","author":"Xia","year":"2015","journal-title":"Oncol Rep"},{"issue":"11","key":"10.1016\/j.bcp.2024.116369_b0140","first-page":"1955","article-title":"Paracrine stimulation of P2X7 receptor by ATP activates a proliferative pathway in ovarian carcinoma cells","volume":"115","author":"Vazquez-Cuevas","year":"2014","journal-title":"J Cell Biochem"},{"issue":"10","key":"10.1016\/j.bcp.2024.116369_b0145","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41568-018-0037-0","article-title":"Extracellular ATP and P2 purinergic signalling in the tumour microenvironment","volume":"18","author":"Di Virgilio","year":"2018","journal-title":"Nat Rev Cancer"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:11:06Z","timestamp":1728346266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224003526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":29,"alternative-id":["S0006295224003526"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116369","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P2X7 receptor deficiency attenuates cisplatin-induced kidney injury via inhibiting NLRP3 inflammasome activation","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116369"}}